Susquehanna International Group, LLP Iveric Bio, Inc. Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$26.24 - $39.63 $7.42 Million - $11.2 Million	-282,755 Reduced 74.85%	94,992 $3.74 Million
Q1 2023 May 16, 2023	BUY	$18.67 - $24.56 $6.27 Million - $8.25 Million	335,989 Added 804.61%	377,747 $9.19 Million
Q4 2022 Feb 14, 2023	SELL	$17.24 - $23.95 $4.66 Million - $6.47 Million	-270,329 Reduced 86.62%	41,758 $894,000
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $1.12 Million - $2.21 Million	118,653 Added 61.34%	312,087 $5.6 Million
Q2 2022 Aug 15, 2022	BUY	$9.12 - $18.9 $760,589 - $1.58 Million	83,398 Added 75.79%	193,434 $1.86 Million
Q1 2022 May 16, 2022	SELL	$12.15 - $16.83 $408,616 - $566,009	-33,631 Reduced 23.41%	110,036 $1.85 Million
Q4 2021 Feb 14, 2022	BUY	$13.83 - $18.78 $753,195 - $1.02 Million	54,461 Added 61.05%	143,667 $2.4 Million
Q3 2021 Nov 15, 2021	BUY	$7.07 - $17.5 $347,023 - $858,970	49,084 Added 122.34%	89,206 $1.45 Million
Q2 2021 Aug 11, 2021	SELL	$5.69 - $7.17 $29,058 - $36,617	-5,107 Reduced 11.29%	40,122 $253,000
Q1 2021 May 17, 2021	SELL	$5.08 - $6.89 $127,802 - $173,338	-25,158 Reduced 35.74%	45,229 $280,000
Q4 2020 Feb 16, 2021	SELL	$5.65 - $7.66 $347,356 - $470,929	-61,479 Reduced 46.62%	70,387 $486,000
Q3 2020 Nov 16, 2020	BUY	$4.01 - $6.29 $275,819 - $432,645	68,783 Added 109.04%	131,866 $744,000
Q2 2020 Aug 14, 2020	SELL	$3.06 - $6.6 $1.02 Million - $2.19 Million	-332,390 Reduced 84.05%	63,083 $322,000
Q1 2020 May 15, 2020	BUY	$2.83 - $8.44 $589,537 - $1.76 Million	208,317 Added 111.31%	395,473 $1.36 Million
Q4 2019 Feb 14, 2020	BUY	$0.93 - $8.58 $174,055 - $1.61 Million	187,156 New	187,156 $1.61 Million

Others Institutions Holding ISEE

# of Institutions

Shares Held

250K

Call Options Held

40K

Put Options Held

View Full List

About IVERIC bio, Inc.

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

More about ISEE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account